P199S100A1 gene therapy protects cardiomyocytes against pro-arrhythmogenic Ca2+ waves and after-contractions

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose

S100A1 has emerged as a key factor in the control of cardiomyocyte (CM) contractile performance in vivo and in vitro and S100A1 gene therapy presents a promising approach for the treatment of heart failure. Improved sarcoplasmic reticulum (SR) function with enhanced Ca2+ resequestration appears critical for its cAMP-independent inotropic effects but raises concerns about potential diastolic SR Ca2+ leakage that might trigger fatal arrhythmias. Thus, the major goal of this study is to determine the impact of S100A1 on the development of diastolic SR Ca2+ leak, triggered Ca2+ waves and after-contractions in response to Ca2+- and cAMP-dependent stressors using cardiac cellular and multi-cellular models as an in vitro test platform.

Methods and Results

Employing confocal Ca2+ imaging, adenoviral-mediated S100A1 overexpression in adult rat CMs revealed both decreased SR Ca2+-spark frequency and prevented β-adrenergic receptor (β-AR)-triggered Ca2+ waves despite augmented SR Ca2+ load compared to controls. Equal efficacy was observed in electrically stimulated failing CMs, where S100A1 overexpression protected against β-AR triggered diastolic Ca2+ waves (occurring in 25% of CMs compared to 83% in controls). Analysis of the apparent protective effect of S100A1 in Engineered rat Heart Tissue (EHT) preparations revealed a profound anti-arrhythmic potency against Ca2+-triggered after-contractions as measured in a shift of EC50 from 1mM to 1.5mM extracellular Ca2+, while inotropy was preserved under isometric load ( + 40% in twitch tension, TT). After chronic endothelin-1 treatment, hypertrophied EHTs exhibited severe contractile failure (-50% in TT compared to control) and pro-arrhythmogenic SR Ca2+ leakage, which could be rescued by adenoviral-mediated S100A1 overexpression. Mechanistically, ryanodine receptor (RyR2) immunoprecipitation confirmed a direct interaction with S100A1 but unveiled unchanged compartmentalized protein kinase A (PKA) and Ca2+/ calmodulin dependent protein kinase II (CamKII) activity as analyzed by RyR2 Ser2808 and Ser2814 phosphorylation.

Conclusion

Our data provide first proof-of-concept for a potential anti-arrhythmic efficacy of S100A1 in CMs using EHT as a test platform. S100A1 appears to convey a rather unique molecular profile combining cAMP-independent inotropy with protection against Ca2+- and β-AR-triggered pro-arrhythmogenic events. Our data point towards the suppression of the SR Ca2+-leak by a direct interaction of S100A1 with the RyR2. Anyhow, further research is clearly needed and ongoing studies focus on the precise molecular interaction of S100A1 at the RyR2.

Related Topics

    loading  Loading Related Articles